Copalis:戦略・SWOT・企業財務分析

◆英語タイトル:Copalis - Strategy, SWOT and Corporate Finance Report
◆商品コード:DATA8015165
◆発行会社(調査会社):MarketLine
◆発行日:2017年9月30日
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:消費財
◆販売価格オプション(消費税別)
Single UserUSD175 ⇒換算¥25,900見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD350 ⇒換算¥51,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD525 ⇒換算¥77,700見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketLine社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
MarketLine社の概要はこちらでご確認いただけます。



【レポートの概要】

Copalis – Strategy, SWOT and Corporate Finance Report
Summary

Copalis – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Copalis is a manufacturer and supplier of marine based natural ingredients. It primarily offers hydrolyzed collagen protein, fish collagen, marine collagen, marine collagen hydrolysate, chondroitin sulphate, elastin, EPA-DHA enriched fish oil, keratin and aromatic extracts among others. The company’s products find application in animal nutrition, human nutrition, nutraceutics, cosmetics, personal care and health-care industries. Copalis, through its subsidiary-SEAnov, manufactures sea food products under the concepts of eco-innovation, gastronomy, and health and nutrition. The company also offers services such as formulation assistance and customized product development. Copalis is headquartered in Le Portel, France.

Scope

- Detailed information on Copalis required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Copalis in the form of a SWOT analysis
- An in-depth view of the business model of Copalis including a breakdown and examination of key business segments
- Intelligence on Copalis ‘s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Copalis , such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of Copalis and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Copalis as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers’ businesses better.
- Stay up to date on Copalis ‘s business structure, strategy and prospects.

【レポートの目次】

Table of Contents
Company Snapshot
Copalis : Company Overview
Copalis : Overview and Key Facts
Copalis : Overview
Copalis : Key Facts
Copalis : Major Products and Services
Copalis : Company History
Copalis : Management Statement
Copalis : Key Competitors
Copalis : Company Analysis
Copalis : Business Description
Copalis : SWOT Analysis
Copalis : SWOT Overview
Copalis : Strengths
Copalis : Weaknesses
Copalis : Opportunities
Copalis : Threats
Appendix
Contact Us
Methodology
Definitions
About MarketLine

List of Tables
Table 1: Copalis : Key Facts
Table 2: Copalis : Key Competitors

★海外企業調査レポート[Copalis:戦略・SWOT・企業財務分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Telkom SA SOC Limited (TKG):企業の財務・戦略的SWOT分析
    Telkom SA SOC Limited (TKG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Eydo Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Eydo Pharma SAS (Eydo Pharma) develops anti-bacterial medicines from essential oils and natural plant molecules for the treatment of infections caused by resistant bacteria. The company developed a pipeline of compounds and formulations such as EP1012, EP1010, EP1011, EP1014, EP1015, EP1020 …
  • Telekom Austria AG:企業の戦略・SWOT・財務情報
    Telekom Austria AG - Strategy, SWOT and Corporate Finance Report Summary Telekom Austria AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The TJX Companies, Inc.:企業の戦略・SWOT・財務情報
    The TJX Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The TJX Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Accent Resources N.L.:企業の戦略・SWOT・財務情報
    Accent Resources N.L. - Strategy, SWOT and Corporate Finance Report Summary Accent Resources N.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nidek Co Ltd:企業の戦略的SWOT分析
    Nidek Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Halo Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Halo Pharma Inc (Halo) is a contract development and manufacturing organization which offers scientific and development expertise services. It offers project management, formulation development and analytical development services. The organization holds specialization in the development of m …
  • XState Resources Ltd (XST):石油・ガス:M&Aディール及び事業提携情報
    Summary XState Resources Ltd (XState Resources) is an oil and gas exploration and development company. The company’s business activities include acquisition, exploration, production and development of oil and gas assets. It holds interest in producing gas wells and associated land leases and product …
  • Vostok New Ventures Ltd (VNV SDB):企業の財務・戦略的SWOT分析
    Summary Vostok New Ventures Ltd (Vostok New Ventures), formerly Vostok Nafta Investment Ltd, is an investment company that identifies and invests in assets. The company carries out partial and complete liquidation of holding and group’s holding companies. It identifies and invests in unlisted compan …
  • ONEOK Partners LP:石油・ガス:M&Aディール及び事業提携情報
    Summary ONEOK Partners, L.P. (ONEOK Partners), a subsidiary of Oneok, Inc., is a midstream energy company. The company carries out gathering, processing, and storage and transportation of natural gas. It operates through master limited partnerships. ONEK Partners owns natural gas liquids (NGL) syste …
  • Caladrius Biosciences Inc (CLBS):企業の財務・戦略的SWOT分析
    Summary Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc, is a clinical-stage biopharmaceutical company. The company develops cellular therapies for the treatment cardiovascular indications and autoimmune diseases. The company's products pipeline includes CLBS03 is an autologous ex vivo p …
  • Center for Applied Medical Research:製薬・医療:M&Aディール及び事業提携情報
    Summary Center for Applied Medical Research (CIMA), a subsidiary of University of Navarra, is a medical research center that carries out research in the therapeutic areas of cardiovascular sciences, gene therapy and hepatology, oncology and neurosciences. The center also offers support services such …
  • SeraCare Life Sciences, Inc.-医療機器分野:企業M&A・提携分析
    Summary SeraCare Life Sciences, Inc. (SeraCare) carries out the discovery, development, manufacture and supply of disease-state specimens and tissues for research and development, processed biological materials, immunoassay reagents and quality control products and technologies. Its major products i …
  • Aalborg Portland Holding A/S:企業の戦略・SWOT・財務情報
    Aalborg Portland Holding A/S - Strategy, SWOT and Corporate Finance Report Summary Aalborg Portland Holding A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Xerox Corporation:企業の戦略・SWOT・財務情報
    Xerox Corporation - Strategy, SWOT and Corporate Finance Report Summary Xerox Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Banco Santander-Chile:企業の戦略・SWOT・財務情報
    Banco Santander-Chile - Strategy, SWOT and Corporate Finance Report Summary Banco Santander-Chile - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • FRONTEO, Inc. (2158):企業の財務・戦略的SWOT分析
    FRONTEO, Inc. (2158) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Super Dragon Technology Co., Ltd. (9955):企業の財務・戦略的SWOT分析
    Super Dragon Technology Co., Ltd. (9955) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • BiosanaPharma BV:製薬・医療:M&Aディール及び事業提携情報
    Summary BiosanaPharma BV (Biosana) is a biotechnology company engaged in the development of monoclonal antibody biologicals (mAbs), biosimilars and biobetters. Its pipeline products include BP001: biosimilar of Omalizumab (anti-allergy); BP002: biosimilar of Denosumab (anti-osteoporosis); BOX001: or …
  • Natra S.A.:企業の戦略・SWOT・財務情報
    Natra S.A. - Strategy, SWOT and Corporate Finance Report Summary Natra S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆